ArticleNeuro-oncology advances
Incidence and real-world burden of brain metastases from solid tumors and hematologic malignancies in Ontario: a population-based study.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Association of Brain Metastases With Survival in Patients With Limited or Stable Extracranial Disease: A Systematic Review and Meta-analysis.JAMA network open · 2023Pooled it
- Incidence of intra-axial brain metastases in Eastern Finland.Journal of neuro-oncology · 2026Article
- The emerging roles of cerebral pericytes in brain metastasis.Neuro-oncology · 2026Review
- Exclusion of patients with brain metastases from early-phase systemic therapy trials: a cross-sectional analysis of eligibility criteria.Journal of neuro-oncology · 2026Article
- Focused ultrasound for brain metastases.Neuro-oncology advances · 2026Review
- Future directions in the treatment of brain metastases: evaluating the role of cellular players in the tumour microenvironment.Acta neuropathologica · 2026Review
- Machine learning identifies prognosticators of intracranial metastatic disease in patients with breast or lung cancer.Communications medicine · 2026Article
- Brain metastases among patients with gynecologic cancers: a single-centre retrospective study of patients treated with brain radiotherapy.Journal of neuro-oncology · 2026Article
- Modality-level attribution and redundancy-aware radiomics for MRI-based differentiation of melanoma and NSCLC brain metastases.Frontiers in oncology · 2026Article
- Unspoken challenges: The hidden struggles of patients under surgical neuro-oncology care.Pakistan journal of medical sciences · 2025Article
- The feasibility of using coplanar-only VMAT combined with "Treat" function to replace non-coplanar VMAT for SRS of 2 to 6 brain metastases.Quantitative imaging in medicine and surgery · 2025Article
- Characterization of the tumor microbiome of brain metastases and glioblastoma reveals tumor-type-specific and location-specific microbial signatures.Nature cancer · 2025Article
- Article
- Hyperglycemia is associated with poor survival in patients with brain metastases treated with radiotherapy.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025Article
- Intraoperative radiotherapy in brain metastasis surgery allows faster transition to systemic therapy.Neuro-oncology practice · 2025Article
- Brain Metastases From Solid Cancers in 58 Dogs.Veterinary medicine and science · 2025Article
- Seizure outcomes in patients with brain metastases and epilepsy: a systematic review on the efficacy of antitumor treatment and antiseizure medication.Neuro-oncology practice · 2025Review
- Case Report: Rare meets rare-miliary prostate cancer brain metastasis.Frontiers in oncology · 2025Article
- Brain metastasis burden and management in patients with small cell lung cancer in Canada: a retrospective, population-based cohort study.EClinicalMedicine · 2024Article
- Multifaceted interactions between cancer cells and glial cells in brain metastasis.Cancer science · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough intracranial metastatic disease (IMD) is a frequent complication of cancer, most cancer registries do not capture these cases. Consequently, a data-gap exists, which thwarts system-level quality improvement efforts. The purpose of this investigation was to determine the real-world burden of IMD.
methodsPatients diagnosed with a non-CNS cancer between 2010 and 2018 were identified from the Ontario Cancer Registry. IMD was identified by scanning hospital administrative databases for cranial irradiation or coding for a secondary brain malignancy (ICD-10 code C793).
results25,478 of 601,678 (4.2%) patients with a diagnosis of primary cancer were found to have IMD. The median time from primary cancer diagnosis to IMD was 5.2 (0.7, 15.4) months and varied across disease sites, for example, 2.1 months for lung, 7.3 months for kidney, and 22.8 months for breast. Median survival following diagnosis with IMD was 3.7 months. Lung cancer accounted for 60% of all brain metastases, followed by breast cancer (11%) and melanoma (6%). More advanced stage at diagnosis and younger age were associated with a higher likelihood of developing IMD (
conclusionIMD represents a significant burden in patients with systemic cancers and is a significant cause of cancer mortality. Our findings support measures to actively capture incidents of brain metastasis in cancer registries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.